Navigation Links
Listing Review initiated by the Toronto Stock Exchange
Date:11/3/2008

TORONTO, Nov. 3 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; PREMF.pk) today announced it has been notified by the Toronto Stock Exchange ("TSX") that it is reviewing the eligibility of the Company's common shares for continued listing on the TSX.

The Company is being reviewed under the TSX's Remedial Review Process and has been granted 210 days to comply with all requirements for continued listing. If the Company cannot demonstrate that it meets all TSX listing requirements on or before June 2, 2009, the Company's common shares will be delisted 30 days from such date. A meeting of the TSX's Listings Committee is scheduled to be held on May 28, 2009 to consider whether to delist the common shares of the Company. The TSX has also advised that, if the TSX becomes aware of additional negative developments such that the continued trading or listing of the Company's shares is contrary to the public interest, an expedited listing review could be initiated.

Over the next months, while the Company awaits their FDA appeal decision and other corporate developments, PreMD will evaluate its options in dealing with the TSX and will provide updates as they become available.

About PreMD Inc.

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products include PREVU* POC and PREVU* LT, both non-invasive skin cholesterol tests. The Company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit http://www.premdinc.com.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the Company's products, the competitiveness of the Company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the Company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions. In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.


'/>"/>
SOURCE PreMD Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Standard Management Announces OTCBB Listing
2. Pharsight Files Application for Nasdaq Capital Market Listing
3. InfoLogix Announces Approval for NASDAQ Listing
4. AKELA Pharma Inc. announces U.S. public offering and proposed listing
5. XTL Announces Delisting From the Official List of the United Kingdom Listing Authority
6. Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange
7. Cash Technologies Discusses AMEX Listing Requirements
8. MedQuist Files Preliminary Proxy Statement and Applies for Listing on NASDAQ
9. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
10. HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ
11. Elbit Imaging Ltd. Selected for Listing on Nasdaq Global Select Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... of its Pflugerville- FM 685 facility. , “We are pleased to announce Dr. ... said Dr. Stephen Van Roekel, Reginal Medical Officer of First Choice Emergency Room – ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... When it ... Parents and guardians deserve clear instructions on how to keep babies and toddlers safe, ... which is Baby Safety Month. , Great Time to Check Labels, Brands that sell ...
(Date:9/19/2017)... ... 19, 2017 , ... With Netmail Hadron, construction ... United States, can easily manage all of their data, apply policies on that ... simultaneously. “As a construction company,” says Ryan Sinnwell, the Infrastructure Manager at The ...
(Date:9/18/2017)... ... September 18, 2017 , ... A September 7 article ... that aspirin, one of the world’s most common and least expensive medications, may be ... dentist Dr. Farzad Feiz of California Dental Group and Calabasas Dental Care says that, ...
(Date:9/18/2017)... ... , ... Allegheny Health Network’s (AHN) string of standout showings at the Pittsburgh ... earned more honors than any health care provider in the region at the annual ... the Omni William Penn Hotel in downtown Pittsburgh included:, , ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... company focused on the development of oral drug delivery ... meeting with the U.S. Food and Drug Administration (FDA) ... At the meeting, the ... submission of ORMD-0801, would be a Biologics License Application ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
(Date:8/29/2017)... , Aug. 29, 2017 In a ... security, and regulatory compliance for veterinary practices of all ... a new partnership that makes TITAN,s expertise in physical ... available to Cubex,s clients nationally. ... buying and handling controlled substances is at risk today," ...
Breaking Medicine Technology: